药物临床试验登记与信息公示平台数据显示,再鼎医药(上海)有限公司的一项评估Povetacicept对比钙调磷酸酶抑制剂治疗原发性膜性肾病疗效、安全性和耐受性的IIb/III期适应性、随机、阳性药物对照研究已启动。临床试验登记号为CTR20253958,首次公示信息日期为2025年10月14日。该药物剂型为注射剂,用法为皮下注射,用量为80mg或240mg,每4周一次,用药时程68周。本次试验IIb...
Source Link药物临床试验登记与信息公示平台数据显示,再鼎医药(上海)有限公司的一项评估Povetacicept对比钙调磷酸酶抑制剂治疗原发性膜性肾病疗效、安全性和耐受性的IIb/III期适应性、随机、阳性药物对照研究已启动。临床试验登记号为CTR20253958,首次公示信息日期为2025年10月14日。该药物剂型为注射剂,用法为皮下注射,用量为80mg或240mg,每4周一次,用药时程68周。本次试验IIb...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.